Sign In
Buy AGNPF
$0.248
-0.0513 (-17.12%)
At Close: Jul 31, 2026
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD
07:00am, Thursday, 30'th Nov 2023
VANCOUVER, British Columbia, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage
VANCOUVER, British Columbia, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical sta
Algernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection with Financial Advisory Agreement
06:00pm, Friday, 14'th Jul 2023
VANCOUVER, British Columbia, July 14, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”), a Canadian clinical sta
Algernon Pharma considers potential spin-off of its chronic cough research program
08:11am, Tuesday, 27'th Jun 2023
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) has said it is considering the potential spin-off of its NP-120 (Ifenprodil) chronic cough research program. The company said it has engaged Maxi
Algernon Pharmaceuticals subsidiary completes DMT escalating dose study
08:11am, Monday, 05'th Jun 2023
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said its subsidiary Algernon NeuroScience (AGN Neuro) has successfully completed dosing of the third and planned final cohort in its escalating dos
Algernon Pharmaceuticals receives Notice of Allowance from Japanese Patent Office for Repirinast
08:34am, Wednesday, 31'st May 2023
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said it has received a Notice of Allowance from the Japanese Patent Office (JPO) for a patent application for its lead chronic kidney disease (CKD
Algernon Pharma receives Notice of Allowance from US Patent and Trademark Office for Repirinast
08:16am, Monday, 17'th Apr 2023
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application for its lead chronic
Algernon Pharmaceuticals announces successful dosing of second cohort in Phase 1 DMT clinical study
07:46am, Tuesday, 04'th Apr 2023
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said its subsidiary Algernon NeuroScience (AGN Neuro) has completed dosing of the second cohort in its escalating dose Phase 1 clinical study of a
Algernon Pharma says wholly-owned subsidiary's Reg A+ offering gets US SEC qualification
07:54am, Monday, 03'rd Apr 2023
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said its wholly-owned subsidiary, Algernon NeuroScience (AGN Neuro), has qualified its Form 1-A offering statement filed with the US Securities and
Algernon Pharmaceuticals to raise $2.4M by way of rights offering
11:51am, Tuesday, 21'st Mar 2023
Algernon Pharmaceuticals Inc announced that it is undertaking a rights offering to raise gross proceeds of approximately $2,416,747. The Canadian clinical stage pharmaceutical development company said
Former NFL neurologist joins Algernon's program using DMT to treat traumatic brain injury
09:48am, Thursday, 02'nd Mar 2023
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) has engaged Dr David Brody, an expert neurologist, as a consultant to support the company's clinical research program for the treatment of Traumati
Algernon Pharmaceuticals says unit initiates traumatic brain injury research program with DMT; appoints global TBI expert as advisor
09:09am, Tuesday, 21'st Feb 2023
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said its subsidiary Algernon NeuroScience (AGN Neuro) has added a new clinical research program for the treatment of Traumatic Brain Injury (TBI)
Algernon Pharma says unit completes dosing of first cohort in its Phase 1 clinical study of an intravenous formulation of DMT
07:59am, Thursday, 16'th Feb 2023
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said its subsidiary Algernon NeuroScience (AGN Neuro), has completed dosing of the first cohort in its Phase 1 clinical study of an intravenous for
Algernon Pharmaceuticals says NeuroScience unit doses first subject in Phase 1 DMT clinical stroke study
08:14am, Tuesday, 17'th Jan 2023
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) told investors that its subsidiary, Algernon NeuroScience (AGN Neuro), has dosed the first subject in its Phase 1 clinical study of an intravenous
Algernon Pharmaceuticals appoints cough study expert Dr Peter Dicpinigaitis as medical advisor
07:52am, Wednesday, 11'th Jan 2023
Algernon Pharmaceuticals Inc told investors that Dr Peter Dicpinigaitis, regarded as an authority on clinical studies of coughs, will be the medical consultant on its Phase 2b clinical study of NP-120
